Start-Up News November 2006

Advances in imaging technologies mean that tiny lung nodules can now be detected, creating a need for technologies for diagnosing and treating lung cancer at early stages. Median Technologies, in computer-assisted detection, PneumRx, with a better biopsy tool, and Perceptronix Medical and Menssana Research, with novel diagnostics, hope to help here.

Lung cancer is the number one cause of cancer deaths in the U.S., in large part because it generally is not detected until it reaches the very late stages. Thus, while therapeutic interventions like photodynamic therapy, laser therapy, brachytherapy, and cryotherapy have made headway in improving survival rates for other types of cancers, survival rates for lung cancer are abysmal. Five-year survival rates for patients diagnosed with lung cancer average just 15.5% (Figure 1).

But the field is poised for change, it seems. A paper published in the October 26, 2006 issue of TheNew...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Medtech Insight

US FDA Unveils Plans To Consolidate Support Services

 

Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.

A Year After Exiting The Ventilator Market, Medtronic Recalls Thousands Of Newport Devices

 

After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.

‘UK Must Put Adoption On A Par With Innovation’

 
• By 

Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.